Bitcoin

Biotech breakthroughs often trigger a wave of venture capital, IPOs, and tokenized asset offerings. In a market where BTC dominance is high and altcoins are sensitive to risk‑on flows, any surge in biotech financing can boost health‑tech tokens and DeFi protocols that stake on R&D pipelines.

CRISPR screening identified claudin-4 as the receptor for a pro-carcinogenic Bacteroides fragilis toxin, leading to E-cadherin cleavage and epithelial barrier disruption.

Nature Paper Identifies Claudin‑4 as Receptor for Cancer‑Linked Bacteroides Toxin

Biotech VCs are quietly seeding crypto wallets to snap up future tokenized patents from the claudin‑4 breakthrough, foreshadowing a new wave of security‑token offerings that could siphon liquidity from BTC.